60
Diamond Score
Phibro Animal Health Corporation
Healthcare · Drug Manufacturers - Specialty & Generic · $2.4B market cap
Overlooked
$59.02
Updated 2026-04-11
Discovery Thesis
AI-generated catalyst thesis will be available after transcript analysis. The quantitative signals below highlight why this company appears to be at an inflection point.
Quantitative summary: 8Q earnings beats, deleveraging, ROIC improving.
Three-Pillar Score Breakdown
Valuation
△ Priced for Growth
PAHC trades at a PEG of 2.99 — the market is pricing in significant future growth.
Inflection Signals
Revenue Acceleration
4Q data
QoQ growth: 0.1247 → 0.0888 → -0.0391 → 0.0275
Margin Expansion
2Q streak
Margins: 0.0964 → 0.089 → 0.1316 → 0.1455
ROIC Trend
3.6%
0.0219 → 0.0223 → 0.0307 → 0.0356
Insider Buying
0 buys (90d)
Debt Paydown
D/E 2.326
2.895 → 2.666 → 2.519 → 2.326
Relative Strength (6M)
59.1%
Earnings Surprise Streak
2026-02-04
+26.1%
$0.87 vs $0.69
2025-11-05
+23.7%
$0.73 vs $0.59
2025-08-27
+9.6%
$0.57 vs $0.52
2025-05-07
+21.2%
$0.63 vs $0.52
Foundation — Business Quality
Revenue Growth (YoY)
27.4%
Overlooked — Why the Market Hasn't Noticed
Analyst Coverage
3 analysts
Very low coverage
Market Cap
$2.4B
Sweet spot ($2-10B)
ETF Inclusion
Not in top ETFs